期刊文献+

CD4^+T淋巴细胞计数检测与HIV病毒载量检测在评价ART效果中的经济性比较及其影响因素 被引量:4

Cost effectiveness of two HIV monitoring methods and its influence factors
原文传递
导出
摘要 目的评价CD4+T淋巴细胞(简称CD4细胞)计数与艾滋病病毒(HIV)病毒载量检测,对于HIV检测与病情诊断和治疗监测的经济性。方法设定检索时间与检索关键词,查阅中英文文献,比较两种检测技术的经济性,并分析其影响因素。结果相比仅依靠CD4细胞计数指导治疗,病毒载量检测指示的抗病毒治疗(ART)能够带来更好的治疗效果和健康结果,但是成本较高。在社会经济发展程度不高的地区,尚没有绝对的证据证明病毒载量检测较CD4细胞计数检测的经济性;而在经济较发达地区,病毒载量检测技术显示出更好的经济性;两种技术共用时,较CD4细胞计数单独使用时往往不具有经济性;仅在南非等经济较发达地区,合并使用两种检测技术更具备成本效果。ICER阈值、具体的检测方案、包含的成本范围以及考虑的健康收益范围,通常是影响经济性评价的重要因素。结论在资源限制的欠发达地区,CD4细胞计数显示出较好的经济性,应优先使用;在经济发展水平较好的地区,可尝试发展和使用病毒载量检测技术,或联合CD4细胞计数共同使用以指导ART。 Objective To evaluate the cost effectiveness of CD4 cell counts and HIV RNA viral load in the testing,diagnosis and monitoring of antiretroviral therapy(ART).Methods Systematic review was made to search the literatures in both Chinese and English.Results Viral load detection provides better treatment effect and health outcomes comparing to merely using CD4 cell counts.HIV RNA viral load test is more cost effective in well developed regions compared to CD4 cell counts,while its cost effectiveness cannot be seen in low-resource settings.Combing the two technologies was not as cost effective as adopting CD4 cell counts alone,except in the well-developed regions such as in the South Africa.ICER threshold,specific testing method,the scope of costs and health benefit included were important factors affecting the results of economic evaluation.Conclusion CD4 cell counts is proven to be more cost effective in resource limited settings and should be given priority to in practice.In wealthier regions,the utilization of viral load test and the combination of the two technologies should be considered to guide ART treatment.
出处 《中国艾滋病性病》 CAS 北大核心 2016年第4期232-236,共5页 Chinese Journal of Aids & STD
基金 上海市第四轮公共卫生三年行动重点学科建设项目循证公共卫生与卫生经济学(15GWZK0901)~~
关键词 CD4^+T淋巴细胞计数 艾滋病病毒载量检测 经济学评价 CD4cell counts HIV RNA viral load Economic evaluation
  • 相关文献

参考文献19

  • 1邵一鸣,康来仪,汪宁,等.中华人民共和国卫生行业标准:艾滋病和艾滋病病毒感染诊断标准[Z].中华人民共和国卫生部,2007.
  • 2白浪,雷秉钧.HIV/AIDS实验室检测及其研究进展[J].中国循证医学杂志,2008,8(3):206-209. 被引量:27
  • 3Lindback S,Karlsson AC,Mittler J,et al.Viral dynamics in primary HIV-1infection[J].AIDS,2000,14(15):2283-2291.
  • 4Quinn TC,Wawer MJ,Sewankambo N,et al.Viral load and heterosexual transmission of human immunodeficiency virus type11Rakai Project Study Group[J].N Engl J Med,2000,342(13):921-929.
  • 5Erice A,Brambilla D,Brember J,et al.Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0assay for detection and quantitation of human immunodeficiency virus type 1RNA in plasma[J].J ClinMicrobiol,2000,38(8):2837-2845.
  • 6Oxford Centre for Evidence-based Medicine.Oxford Centre for Evidence-based Medicine-Levels of Evidence(March 2009)[EB/OL].[2014-4].http://www.cebm.net/oxford-centre-evidencebased-medicine-levels-evidence-march-2009/.
  • 7FDrummond M.卫生保健项目经济学评价方法[M].3版.北京:人民卫生出版社,2008:6.
  • 8Geneva:World Health Organization.Antiretroviral Therapy for HIV Infection in Adults and Adolescents:Recommendations for a Public Health Approach:2010Revision[EB/OL].2010.Available from:http://www.ncbi.nlm.nih.gov/books/NBK138540/.
  • 9P.Hyle EE,Sax P,Walensky RP.Potential Savings by Reduced CD4Monitoring in Stable Patients with HIV Receiving Antiretroviral Therapy[J].JAMA Internal Medicine,2013,173(18):2013-2015.
  • 10Koenig SP,Bang H,Severe P,et al.Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti[J].PLoS Medicine,2011,8(9),e1001095.

二级参考文献28

  • 1郑晓丽.HIV检测研究进展与发展趋势[J].现代检验医学杂志,2004,19(6):64-67. 被引量:13
  • 2Lindback S, Karlsson AC, Mittler J, et al, Viral dynamics in primary HIV-1 infection, AIDS, 2000, 14(15): 2283-2291.
  • 3Mellors JW, Munoz A, Giorgi JV, et al. Plasma Viral Load and CD4^+ Lymphocytes as Prognostic Markers of HIV-1 Infection. Ann Intern Med, 1997, 126: 946-954.
  • 4Abravaya K, Esping C, Hoenle R, et al, Performance of a Multi plex Qualitative PCR LCx Assay for Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Subtypes, Group O, and HIV-2. J Clin Microbiol, 2000, 38(2): 716-723.
  • 5Zhao YQ, Min Y, Miller JW, et al. Quantification of Human Immundeficiency virus type 1 Proviral DNA by Using TaqMan Technology. J Chin Microbiol, 2002, 40(2): 675-678.
  • 6Leroy V, Montcho C, Manigart O, et al, Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial. AIDS, 2001, 15(4): 517-522.
  • 7Deeks S, Beatty G, Cohen PT, et al. Viral load and CD4^+ T cells changes in patients failing potent protease inhibitor therapy. Presented at the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Abstract 419.
  • 8Edelstein RE, Nickerson DA, Tobe VO, et al, Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 pol Gene That Are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine. J Clin Microbiol, 1998, 36(7): 569-572.
  • 9Riddler S, Mellors JW. Clinical use of Viral Load Measures. MMWR, April,1998.
  • 10Mellors JW, Rinaldo CR, Gupta P, et al, Prognosis in HIV-1 Infection Predicted by the Quantity of virus in plasma, Science, 1996, 272(5): 1167.

共引文献26

同被引文献32

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部